Cyber Incident Victim: Tissue Regenix Group PLC
Date:
Jan 2020
Location:
United States of America
Summary
A UK-based medical technology company experienced unauthorized access to its computer systems and a third-party IT provider in the US, prompting the temporary shutdown of its American manufacturing plant. The company took affected systems offline and engaged forensic cybersecurity specialists and legal authorities to investigate the breach, which did not impact UK operations or financial systems. The incident caused a significant decline in share price and occurred amid existing concerns over the firm's funding stability beyond April.
| CIA Posture | Motives | Tactics, Techniques & Procedures |
|---|---|---|
| Available to members | 3 motives | 3 techniques |
| Threat Actors | Type | Location |
|---|---|---|
| 0 actors | Available to members | Available to members |
Description
On January 28, 2020, UK-based regenerative medical technology company Tissue Regenix Group PLC disclosed a cybersecurity breach involving unauthorized access to its computer systems and those of a third-party IT service provider in the United States. The company did not specify the intrusion method, timeline of compromise discovery, or attacker identity. In response, Tissue Regenix immediately took affected systems offline as a precautionary measure, resulting in the temporary shutdown of manufacturing operations at its Texas facility. The company engaged forensic cybersecurity specialists to investigate the breach's origin and scope while coordinating with legal authorities. Operations at UK facilities remained unaffected, and financial systems were not compromised during the incident.
The manufacturing disruption at the Texas plant created immediate operational impacts, halting production of the company's specialized tissue grafts used for human body part repairs. Tissue Regenix confirmed the breach occurred during a period of financial uncertainty, having previously disclosed funding challenges extending beyond April 2020. News of the cybersecurity incident triggered a 22% decline in the company's share price on the day of disclosure. Resolution timelines remained undetermined as Tissue Regenix collaborated with its third-party IT provider and cybersecurity experts to restore systems. The company maintained communication with relevant legal entities throughout the containment and investigation process without disclosing regulatory notifications or data compromise specifics.